Kazia Therapeutics (ASX: KZA) on track to announce clinical trial data from its two key programs announced in robust half-yearly report

KEY TAKEAWAYS:

  • 2019 sees Kazia on track to achieve multiple data readouts from their two leading clinical programs, GDC-0084 and Cantrixil.
  • Both programs are on track to deliver key clinical trial data, vital in securing future investor focus.
  • Kazia is currently sitting with a robust bottom line heading into 2019 with key collaboration partnerships in place.

2019 sees Kazia on track to achieve multiple data readouts from two clinical programs (GDC-0084 and Cantrixil) that will deliver key clinical trial data, a crucial element in securing business partners and investor focus.

The GDC-0084 program currently comprises three active clinical studies in brain cancer, conducted in leading US hospitals under the rigorous oversight of the US Food & Drug Administration (FDA).

The first key clinical study, GDC-0084, is being developed in glioblastoma, the most common and most aggressive form of primary brain cancer. Initial data is due in the first half of 2019 with further results at end of the year. Positive results from the extensive data read would help to elevate Kazia to the world stage in regard to the treatment of brain cancer.

Two key partnerships were announced in October 2018 due to roll out this year. Firstly, a collaboration with St Jude Children’s Research Hospital in a phase I trial of GDC-0084 in diffuse intrinsic pontine glioma (DIPG), a rare and highly aggressive form of childhood brain cancer. Secondly, further collaboration with Dana-Farber Cancer Institute to begin a phase II trial of GDC-0084 in breast cancer brain metastases (BCBM), when breast cancer has spread to the brain.

The Cantrixil program is progressing with a phase I study in ovarian cancer underway and advancement made in Part B of the study seeking preliminary signs of efficacy.

Kazia announced a cash balance at 31 December 2018 of $5.4 million with liquid assets standing at $11.1 million and $5.8 million spent on advancing the company’s R&D pipeline, representing two-thirds of the company’s expenditure. The Share Purchase Plan has raised a further $0.8 million from over 130 shareholders, taking total funding to date to $4.2 million.

Kazia Therapeutics is pleased to make its February 2019 newsletter available to investors via this link

 

About Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA)

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is developing cancer treatments for areas which there is a high unmet medical need. Our lead program, GDC-0084, a drug to treat glioblastoma multiforme, the most aggressive brain cancer, has completed phase 1 human trials with strong safety and early efficacy signals. It is currently being prepared for phase 2 human trials.

Register Interest